Loading...
•
Jun 30, 2022
Sera Prognostics Q2 2022 Earnings Report
Sera Prognostics' financial results for Q2 2022 were announced, highlighting a revenue increase compared to the same period last year and ongoing efforts to expand the adoption of the PreTRM® Test.
Key Takeaways
Sera Prognostics reported a revenue of $78,000 for the second quarter of 2022, compared to $20,000 for the same period in 2021. The company's net loss for the quarter was $11.5 million, and they had approximately $121 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2022.
Revenue increased to $78,000 in Q2 2022 from $20,000 in Q2 2021.
Operating expenses rose to $11.8 million, compared to $7.4 million in the same quarter last year.
Net loss for the quarter was $11.5 million, up from $6.3 million year-over-year.
The company had approximately $121 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2022.
Forward Guidance
The company anticipates additional clinical and health economic publications that further illustrate the clinical utility and benefit of PreTRM® technology, supporting the achievement of their vision to improve the well-being of mothers and newborns and decreasing healthcare costs. The Company extending its operations into 2026 without the need for additional financing.
Positive Outlook
- Healthcare systems aligning on incorporating PreTRM testing as an add-on to comprehensive services provided to pregnant women.
- Expanded adoption of the PreTRM® Test
- Demonstrable progress in contracting with self-insured employers
- Additional clinical and health economic publications that further illustrate the clinical utility and benefit of PreTRM® technology
- The Company extending its operations into 2026 without the need for additional financing
Challenges Ahead
- Net losses
- Cash generation
- The potential need to raise more capital
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...